Banco Santander S.A. Sells 26,657 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 23rd, 2023

Banco Santander S.A. lowered its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 18.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 120,846 shares of the company’s stock after selling 26,657 shares during the period. Banco Santander S.A.’s holdings in Johnson & Johnson were worth $18,731,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GW&K Investment Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $35,000. Dark Forest Capital Management LP lifted its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $42,000. Kepos Capital LP purchased a new position in Johnson & Johnson in the 4th quarter worth $45,000. Finally, FWL Investment Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $114,000. 67.57% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock worth $7,928,856 over the last three months. 0.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Atlantic Securities boosted their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Stifel Nicolaus increased their target price on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Raymond James upped their price target on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. Finally, Citigroup started coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $171.80.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE JNJ opened at $166.01 on Wednesday. The stock has a market capitalization of $431.45 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 2.89 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $166.56 and its 200-day moving average price is $161.43.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.59 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.75 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.